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 Abstract:  
  
Objective: A hitherto undescribed phenotype of early onset muscular dystrophy associated with 
sensorineural hearing loss and primary ovarian insufficiency was initially identified in two 
siblings and in subsequent patients with a similar constellation of findings. The goal of this study 
was to understand the genetic and molecular etiology of this condition. 
Methods: We applied whole exome sequencing (WES) superimposed on shared haplotype 
regions to identify the initial biallelic variants in GGPS1 followed by GGPS1 Sanger sequencing 
or WES in five additional families with the same phenotype. Molecular modeling, biochemical 
analysis, laser membrane injury assay and the generation of a Y259C knock-in mouse were 
done. 
Results: A total of 11 patients in six families carrying five different biallelic mutations in specific 
domains of GGPS1 were identified. GGPS1 encodes geranylgeranyl diphosphate synthase in 
the mevalonate/isoprenoid pathway, which catalyzes the synthesis of geranylgeranyl 
diphosphate (GGPP), the lipid precursor of geranylgeranylated proteins including small 
GTPases. All but one patient presented with congenital sensorineural hearing loss and proximal 
weakness, and all post-pubertal females had primary ovarian insufficiency. Muscle histology 
was dystrophic with ultrastructural evidence of autophagic material and large mitochondria in 
the most severe cases. There was delayed membrane healing after laser injury in patient 
derived myogenic cells while a knock-in mouse of one of the mutations (Y259C) resulted in 
prenatal lethality.  
Interpretation: The identification of specific GGPS1 mutations defines the cause of a unique 
form of muscular dystrophy with hearing loss and ovarian insufficiency and points to a novel 
pathway for this clinical constellation. 
 








The muscular dystrophies are degenerative disorders of muscle characterized by evidence of 
degeneration and regeneration on muscle histology and are typically associated with elevated 
creatine kinase (CK) as a measure of ongoing muscle fiber breakdown. Mechanisms and 
pathways which underlie muscular dystrophies are diverse and include extracellular, membrane 
centered, sarcomeric, nuclear, mitochondrial as well as metabolic mechanisms.1 In the 
dystrophies that involve membrane stability or repair, serum CK values are typically elevated as 
a sign of membrane leakage. Congenital sensorineural hearing loss rarely manifests in 
association with muscular dystrophy but has been reported in early onset facioscapulohumeral 
muscular dystrophy.2 Perrault syndrome, caused by mutations in various mitochondrial and 
peroxisomal genes, clinically manifests with sensorineural hearing loss and primary ovarian 
insufficiency but without muscle involvement,3 while a combination of muscular dystrophy with 
primary ovarian insufficiency has not been recognized yet. 
 
The mevalonate pathway is a central metabolic shuttle for the synthesis of specialized lipids. 
Mevalonic acid is formed from acetyl-CoA via HMG-CoA and then further metabolized to 
isopentenyl-5-PP (IPP) which is subsequently converted to farnesyl-PP (FPP), which serves as 
a precursor for the squalene cholesterol pathway as well as for protein prenylation4, which 
includes farnesylation as well as geranylgeranylation. Prenylation adds a hydrophobic lipid tail 
to proteins allowing for anchorage to membranes for precise subcellular localization, typically 
within membranes. Prenylation is of particular relevance for small GTPases, including those of 
the Rho and Ras/Rab families. For geranylgeranylation, FPP has to be converted to 
geranylgeranyl-PP (GGPP), by geranylgeranyldiphosphate synthetase (GGPPS, EC:2.5.1.29), 
encoded by GGPS1. Geranylgeranyl pyrophosphate (GGPP) will then be transferred by two 
types of geranylgeranyl transferases (GGTase I or GGTase II) onto the recipient proteins. While 
some of the small GTPases are only farnesylated or can alternatively be farnesylated or 
geranylgeranylated, some are exclusively dependent on geranylgeranylation for their 
prenylation. More than 100 human proteins are predicted to be targets for geranylgeranylation, 
amongst them are prominently small GTPases of the Rab family, many of which are involved in 
tagging membranes of ER, Golgi, endosome Golgi, lysosome autophagic vesicle, cell 
membranes, mitochondria and as well of the Rho/Rac family involved in cytoskeletal actin 
dynamics amongst other roles.5,6,7 Other functions of GGPP include negative feedback 
regulation of the mevalonate pathway by inducing HMG-CoA reductase misfolding, 
ubiquitination and degradation.8 Some GGPP may also enter into ubiquinone, coenzyme Q and 
squalene synthesis; however, FPP is the major source for this biosynthetic branch. It is also 
possible that there are additional, not yet explored functions and uses for GGPP in the cell.9 
While thus far there has been no human monogenic disease linked to mutations in GGPS1, it 
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has been identified as a risk factor for atypical femoral bone fractures in females exposed to 
bisphosphonates.10,11,12 
 
Here we report specific mutations in the gene GGPS1 coding for the enzyme geranylgeranyl 
pyrophosphate synthetase in 11 patients from 6 families causing a highly distinctive syndrome 
of early onset muscular dystrophy combined with congenital sensorineural hearing loss and 
primary ovarian insufficiency in females. The mutations do not abolish enzymatic activity of this 
essential enzyme but with a highly distinctive genotype/phenotype correlation define the 
mevalonate pathway as essential for muscle, hearing and endocrine functions. 
 
 
Subjects/Materials and Methods 
 
Patient Recruitment and Sample Collection Patients P1, P2 and P7 were consented and 
enrolled in the study approved by the institutional review board (IRB) of the National Institute of 
Neurological Disorders and Stroke, National Institutes of Health (12-N-0095). Patient 3 was 
enrolled via the Institute of Genetic Medicine, International Centre for Life’s Biobank [NRES 
Committee North East - Newcastle & North Tyneside; Research Ethics Committee (REC) 
reference:  08/H0906/28+5]. Patients P4-P6 and patient P8 were enrolled via the Institut de 
Myologie and AP-HP, Groupe Hospitalier La Pitié-Salpêtrière (REC reference: AC-2018-3156). 
Patients P9-11 were consented and enrolled to the MYOGENE project, approved by the Institut 
de Génétique et de Biologie Moléculaire et Cellulaire IRB (DC-2012-1693). Tissue (DNA and 
skin fibroblasts) were obtained based on standard procedures. Muscle biopsies were obtained 
as part of the regular clinical diagnostic testing and were evaluated by standard light and 
electron microscopy protocols.  
 
Molecular Genetic Analyses of Patients Whole exome sequencing (WES) was performed in 
the two index patients (P1, P2) at the NIH Intramural Sequencing Center using the Illumina 
TruSeq Exome Enrichment Kit, and Illumina HiSeq 2500 sequencing instruments and was 
combined with haplotype analysis in the entire family (as described13). Assuming autosomal 
recessive inheritance in a non-consanguineous family, the haplotype data was analyzed to 
identify regions of shared haplotypes between the two affected siblings but not their unaffected 
siblings or parents. WES was performed in the two affected siblings (P1, P2) and analyzed for 
biallelic rare variants that were predicted to be damaging and shared between them. Given the 
highly specific appearing clinical phenotype in the index family, an additional 6 patients (P3-8) in 
4 families were identified in neuromuscular centers in Europe and Asia. DNA was analyzed by 
direct Sanger sequencing of the candidate gene. In one additional family, GGPS1 mutations 
were identified in three affected siblings (P9-11) via WES, which was performed using the 
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SureSelect Human all Exon 50Mb capture library v5 (Agilent), and the Illumina HiSeq2500 
platform. Sequence data were aligned to the GRCh37/hg19 reference genome, variants were 
annotated and filtered based on their frequency in gnomAD (http://gnomad.broadinstitute.org/) 
and in-house database containing >1500 exomes, and the impact of the variants was predicted 
using SnpEff (http://snpeff.sourceforge.net/). 
 
Histology and Immunohistochemical Staining Muscle biopsies and skin biopsies were 
processed following standard procedures. Dermal fibroblasts derived from skin biopsies were 
cultured as described previously.14 Some of the dermal fibroblasts were converted to myoblast 
with Lenti-MyoD lentiviral system (Clontech Laboratories, Mountain View, USA). Cultured 
fibroblasts and muscle cryosections were processed with standard immunohistochemical 
staining method.14 The following antibodies were used for immunohistochemical staining: 
GGPS1 (N-term, Abcepta, San Diego, USA), desmin (clone DE-U-10, Sigma Aldrich, Saint 
Louis, USA), LC3b (D11, Cell Signaling Tech., Beverly, USA) and ATP synthase beta 
(ThermoFisher Scientific, Waltham, USA). Confocal images were captured with Leica SP5 
confocal laser scanning microscope. 
 
GGPPS Enzyme Activity Assay and Conformation Analysis Wild type and mutant GGPPS 
identified in the patients were expressed in a bacterial expression system, enzyme activity was 
assayed using substrates, Farnesyl pyrophosphate (FPP) and C14-isopentenlyl pyrophosphate 
(IPP) as described previously.12 The GGPPS activities in Lenti-MyoD converted myoblasts of 
normal controls and patients were also assayed as described before.15 The oligomerization of 
wild type and mutant GGPPS expressed in bacterial system was measured by gel filtration 
chromatography using an ÄKTA Explorer as described previously.12 
Generation of a Ggps1 p.Y259C Knock‐In Mouse A knock-in mouse was generated under 
contract at genOway (genOway, Lyon, France) by insertion of a Y259C point mutation in exon 
5a of the Ggps1 gene (located 633 bp downstream of the 5’ end of exon 5a). The mutated 
Ggps1 gene is expressed under the control of the endogenous Ggps1 promoter. In addition, the 
Ggps1 exon 4 is flanked by a validated FRT-neomycin-FRT-loxP cassette and by a single loxP 
site enabling the conditional deletion of the Ggps1 gene. The FRT-neomycin-FRT-loxP cassette 
and the single loxP site are positioned as illustrated in Figure 7A.  
Cell Membrane Repair Assay Dermal fibroblasts derived from normal controls and patient (P6) 
were MyoD transfected using Lenti-MyoD, converted to myoblasts and further differentiated to 
myotubes.  These cells were tested in separate experiments for their cell membrane repair 
kinetics following focal pulsed laser injury in the presence of the cell impermanent dye FM1-43  
 and following the dye intensity as described.16  
 





Clinical Phenotype  
The index patient (P1) (Fig 1) manifested symptoms prenatally with decreased fetal movements, 
and neonatally with a weak cry and a poor suck. By 12 months of age she was diagnosed with 
bilateral sensorineural hearing loss [via brainstem auditory evoked response (BAER) testing]. 
She had delayed early motor milestones and walked independently at 18 months of age. She 
had intermittent episodes of diarrhea accompanied by poor feeding, muscle weakness, elevated 
creatine kinase (CK) (up to 18,025 U/L at 19 months of age). Progressive muscle weakness and 
contractures resulted in full-time wheelchair use by 11 years of age. She developed respiratory 
insufficiency, necessitating non-invasive ventilation, progressing to tracheostomy. Progressive 
scoliosis necessitated spinal fusion at age 11 years. At 14 years of age she had a gastrostomy 
tube placed for failure to thrive. She had amenorrhea, and following an endocrinologic 
evaluation was diagnosed with primary ovarian insufficiency. The index patient’s younger 
brother (P2) presented with a similar phenotype (Table 1) with congenital sensorineural hearing 
loss, muscular dystrophy with intermittent high elevations in CK (up to 11,250 U/L), respiratory 
insufficiency and scoliosis. His fertility remains unknown, and he has not undergone a formal, 
endocrinologic evaluation.   
 
A further nine patients in five families with recessively inherited mutations in GGPS1 were 
subsequently identified, using direct GGPS1 sequencing based on a suggestive phenotype 
(patients P3, P4, P5, P6, P7 and P8) or analysis of whole exome sequencing results (patients 
P9-P11) (Table 1). Patient P3 was born prematurely (29 weeks gestational age) and was 
diagnosed with congenital sensorineural hearing loss. He carries compound heterozygous 
mutations in GGPS1 (R261G; P15S) and has a phenotype most similar to P1 and P2, with 
whom he shares the R261G mutation. Like patients P1 and P2, patient P3 has had variably 
elevated CK values (up to 6,641 U/L) and has developed respiratory insufficiency, wheelchair 
dependence, scoliosis and failure to thrive. In Family 3, three of six children are affected and 
carry homozygous R261H mutations in GGPS1, manifesting with a milder motor phenotype in 
that they all have muscle weakness but achieved the ability for a slow run and have maintained 
independent ambulation into adulthood. All have sensorineural hearing loss, and both affected 
females have been formally diagnosed with primary ovarian insufficiency. The male has not 
undergone a formal endocrinologic evaluation but has no offspring at 45 years of age. Patient 
P7 in Family 4 is also homozygous for the R261H mutation in GGPS1 and also manifests a 
comparatively milder phenotype from a motor perspective. At 14 and ½ years of age she 
remains independently ambulatory. Patient P8 in Family 5 is homozygous for the F257C 
mutation in GGPS1 and was diagnosed with congenital sensorineural hearing loss. At the time 
of his last assessment at 14 years of age, he remained independently ambulatory. In Family 6 
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three of five children (patients P9, P10 and P11) were identified via WES to carry homozygous 
F257C mutations in GGPS1, resulting in a moderate-to-severe phenotype with all three siblings 
manifesting muscle weakness and failure to thrive. The oldest sibling (a 22-year-old male) has 
been a full-time wheelchair user since 12 years, has respiratory insufficiency and scoliosis. Of 
the younger (female) siblings, the 11-year-old uses a wheelchair full-time, while the 8-year-old 
remains independently ambulatory.  
 
Thus, progressive muscle weakness and joint contractures resulting in loss of independent 
ambulation, respiratory insufficiency necessitating ventilation dependence and severe scoliosis 
were seen in patients P1, P2, P3 and P9, while the other patients had a less severe progression 
of weakness.  Sensorineural hearing loss was present in all but one patient in this cohort and 
was the first symptom identified in those patients with milder motor phenotypes. Given that the 
hearing loss was diagnosed in some patients in the neonatal period and in others during 
childhood, the onset is likely congenital, since diagnosis relies on a formal audiometric 
evaluation. Primary ovarian insufficiency (POI) also known as premature ovarian failure has 
been diagnosed in all post-pubertal females in this cohort, as confirmed by menopausal levels 
of follicle stimulating hormone (FSH) in the setting of a history of amenorrhea [P1 (FSH: 88.2 
IU/L)] or infertility [P4 (FSH: 50.3 IU/L) and P6 (FSH: 53.2 IU/L ). Eight patients had evidence of 
failure to thrive and/or short stature, potentially suggestive of further endocrinologic involvement. 
Of note, no cardiac or cognitive involvement has been noted in this cohort.  
 
Whole-body muscle MRI was performed in patients P4, P5 and P6 and demonstrates variable 
increase in T1 signal in select muscles, resulting from fatty infiltration and thus consistent with 
an underlying muscular dystrophy (Fig 1C). It is notable that these 3 patients all demonstrate 
relative sparing of the rectus femoris, sartorius and gracilis muscles. Clear asymmetry of muscle 
involvement and heterogeneously distributed abnormal T1 signal in the hamstrings is 
appreciated in patients P5 and P6.  
 
Muscle biopsies were performed in 9 patients (P1-P9). Histology was dystrophic with evidence 
of degeneration and regeneration and internalized nuclei. There were occasional rimmed 
vacuoles while the oxidative stains had peripherally increased oxidative reactivity in some fibers 
and core-like regions in other fibers. Electron microscopy revealed ultrastructural evidence of 
enlarged but structurally normal mitochondria (P8) as well as evidence of excess autophagic 
material (P1and P8) (Fig 2). The CoQ10 level in muscle was determined to be normal in patient 
P1. Of note, patient P3 was given an empirical treatment trial of oral CoQ10, which did not result 
in any noted improvement of symptoms. 
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In summary, GGPS1-related muscular dystrophy/hearing loss is characterized by a remarkably 
consistent and recognizable phenotype of congenital sensorineural hearing loss, primary 
ovarian insufficiency in females, proximal muscle weakness with episodes of variably elevated 
CK, scoliosis and respiratory insufficiency, in which the symptoms are progressive in nature and 
can be severe. Muscle histological and ultrastructural findings are consistent with a dystrophic 
process with evidence of abnormal autophagy and mild mitochondrial changes. 
 
Gene Identification and Mutations  
In the index family whole exome sequencing in the two index patients (P1 and P2) was 
combined with haplotype analysis on the entire family which ruled out 97.3% of the exome, 
leaving 2.07% consistent with recessive compound heterozygous inheritance. The compatible 
region was distributed on three separate regions on chromosome 1, and one region on 
chromosome 3, covering 55,538,583 bp, and containing 745 genes. Subsequently, WES data in 
P1 and P2 was analyzed for shared biallelic rare variants that were predicted to be damaging. 
Two variants (p.Y259C and p.R261G) in the geranylgeranyl diphosphate synthase 1 or GGPS1 
gene located in one of the compatible regions on chromosome 1 were identified as the only 
likely candidates to be responsible for the phenotype in this family. Both were extremely rare, 
p.Y259C was not present in gnomAD (Genome Aggregation Database) 
(https://www.biorxiv.org/content/10.1101/531210v3), while p.R261G was listed once, and both 
were predicted to be damaging [Polyphen prediction score of 1.000 and 0.711 for p.Y259C and 
p.R261G respectively]. Mutation and segregation in the family were confirmed by Sanger 
sequencing.  
  
Given the highly specific appearing clinical phenotype in the index family, an additional six 
patients in four families were identified in neuromuscular centers in Europe and Asia and 
analyzed by direct sequencing of GGPS1. One additional family (Family 6) with three affected 
siblings was identified by WES. In all patients, we identified biallelic pathogenic variants in 
GGPS1; four families were found to be homozygous, and in the remaining family compound 
heterozygous variants were identified. In all families missense variants were identified: F257C 
(2 families), R261H (2 families), and R261G in compound heterozygosity with: P15S in Family 2 
(P3) and Y259C in Family 1 (P1 and P2). Allele (AF) frequencies as determined in gnomAD 
were very low: [P15S; AF=0] [F257C; AF=0] [Y259C; AF=0] [R261G; AF=0.00003] [R261H; AF= 
0.00002]. Rare heterozygous carriers for loss-of-function variants in GGPS1 are listed in 
gnomAD and should therefore be asymptomatic. The pathogenic variants fell within a specific 
five amino acid region towards the C terminus around the start of helix 11 as of yet unclear 
function (Fig 3A). In animals, geranylgeranyl diphosphate synthase is formed as a hexamer and 
in certain circumstances as an octamer, while in plants it is a dimer.17 In silico modeling of 
GGPPS hexamer shows that this domain, in which all but one of the pathogenic variants (P15S) 
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were clustered, is located towards the outside of the hexamer and not in the barrel where the 
catalytic core of the enzyme is located (Fig 4A). The first α-helix containing the P15S mutation is 
conserved and involved in the formation of the trimer from the dimers (Fig 3A). While the 
catalytic domain itself is highly conserved across plants and animals, the mutated five amino 
acid domain is highly conserved in animals but not in plant ggps1, suggesting a function beyond 
the basic enzymatic activity of the enzyme in animals cells (Fig 3A). 
 
We were unable to generate a crystal structure of mutant GGPPS, while in silico modelling of 
the pathogenic variants did not result in major conformational or charge distribution changes of 
the 11th alpha helix (Fig 4B-D); only R261G results in the loss of a positive charge (Fig 4E,F).  
 
Immunohistochemical Analysis  
In primary human dermal fibroblast GGPPS immunocytochemistry revealed a rather uniform 
cytoplasmic expression consistent with its known cytosolic localization, 18 along with signals 
concentrated at some organelles and the perinuclear region (Fig 5A).  There was no obvious 
difference in this pattern in patients, as seen in P1 compared to controls. In longitudinal sections 
of control human muscle, GGPPS immunohistochemistry showed prominent localization to the 
Z disc, which was labeled with desmin (Fig 5B). In patients, there was no deficiency of GGPPS 
immunoreactivity compared to controls; in fact, it appeared brighter and showed some focal, 
subsarcolemmal accumulation, partially co-localizing with the mitochondrial marker ATP 
synthase beta (Fig 5C).  
 
Enzymatic Activity  
We first measured enzyme activity of wild type and mutant GGPPS expressed on bacteria. 
Using 10uM FPP/IPP as a substrate on showed that the P15S mutant had the same activity as 
wild type; however, the other mutants (F257C, Y259C, R261G, and R261H) consistently 
showed a reduced rate of activity of approximately 70-85% of wild type (Fig 6A). Activity assays 
performed with 20uM FPP/IPP in the presence of 20uM GGPP (thus a concentration of GGPP 
just below the concentration required for product inhibition in the wild type enzyme) also had no 
effect on the enzyme activity in the mutants, suggesting that the mutations were not causing 
abnormal product release issue or an increase in their sensitivity to product inhibition (data not 
shown). Next we measured GGPPS enzymatic activity in Lenti-MyoD-converted myoblasts of 
normal controls and patients (Fig 6B). We found that enzymatic activity in samples pooled from 
4 patients (P1, P2, P6 and P8) was decreased to about 50% of the activity in a pooled normal 
control sample. 
 
GGPPS Conformation   
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GGPPS has been shown to be hexameric in structure as a trimer of dimers.15 The size of the 
enzyme produced in the bacterial expression system in solution was measured using gel 
filtration chromatography. We found that mutant enzymes eluted essentially at a similar point to 
the wild type enzyme (Fig 3C). The molecular weight of each mutant enzyme was in the 
expected range of 240-255KDa, suggesting the complexes are hexameric. There was a small 
amount of aggregated protein apparent for mutants Y259C, R261H and R261G which eluted 
with the void volume, but no indication of any smaller enzyme unit such as the dimerCell 
Membrane Repair Following Focal Injury  
Patient fibroblasts were used to generate myoblasts, which were then differentiated into 
myotubes prior to testing the cell membrane repair kinetics and the ability of these cells to repair 
from focal laser injury as described.16 We observed greater dye entry, indicating a poor cell 
membrane repair, in both the patient myoblasts and myotubes as compared to the healthy 
controls (Fig 6C,E traces). Consequently, there was about a 2-fold increase in the number of 
patient myoblasts that failed to repair (Fig 6D). Interestingly, despite the experimental challenge 
associated with the greater fragility of myotubes grown on a dish, which results in many more 
myotubes (compared to myoblasts) detaching upon injury, the patient myotubes demonstrated a 
2-fold reduction in their ability to survive focal injury as compared to the control myotubes (Fig 
6F).    
Ggps1 p.Y259C Knock‐In Mouse   
Given that total enzymatic activity was only moderately decreased in vitro, and the fact that the 
identified mutations cluster in a very narrow, externally facing domain outside of the catalytic 
core of the enzyme, we surmised that the human disease-associated mutations would likely 
only interfere with a highly specific function or subcellular localization of the protein to explain 
the very specific clinical phenotype. As a total knockout the gene is not viable, we therefore 
created a knock-in mouse of the mutation p.Y259C (Fig 7A) detected in compound 
heterozygosity in the index family (Family 1) to study the effects of the mutant GGPS1 on the 
organismal level. We chose this mutation with the highest Polyphen score in order to maximize 
our chances of detecting a phenotype in the mouse, as knock-in models of human missense 
mutations are frequently insufficiently penetrant. We were surprised to find that no litter included 
homozygous mutant animals. Timed pregnancies (Fig 7B-P) revealed that homozygote Y259C 
knock-in embryos developed up to ED12.5 with no live embryos observed after this point. No 
gross developmental abnormalities but a dramatically slowed rate of development was evident 
at ED10.5 when homozygous Y259C knock-in embryos more closely resembled a wild type 
embryo at ED9.5, while at ED12.5 they resembled the typical development observed in wild 
type embryos at ED10. Thus, detailed mechanistic studies relevant to the human phenotype 
were not possible in this mouse strain.  
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Discussion   
There are three important clinical dimensions to this recognizable syndrome: muscular 
dystrophy, hearing loss, and infertility. The muscular dystrophy ranged from prenatal/congenital 
onset with progression to loss of ambulation and respiratory failure in early teenage years, to 
milder manifestations with preserved ambulation into adulthood (Table 1). In P1, P2 and P7 
there was a history of episodic worsening of weakness concomitant with higher CK elevations 
during episodes of diarrhea. Muscle MR imaging performed in Family 3 (Fig 1C) revealed 
variable evidence of fatty replacement of muscles consistent with a muscular dystrophy. The 
relative sparing of the rectus femoris, sartorius and gracilis muscles and asymmetric 
involvement of muscles in this clinical context may be diagnostically helpful but can also be 
observed in other muscular dystrophies. Imaging of additional patients will be required to assess 
whether a consistent pattern will emerge. Muscle histology in six patients confirms degenerative 
features of muscular dystrophy but with ultrastructural findings of disordered autophagy and 
larger, but structurally normal-appearing, mitochondria, pointing to potential involvement of 
these organelles (Fig 2). 
 
To our knowledge, this triad of clinical findings has not been seen in another form of muscular 
disease. Notably, the sensorineural hearing loss (confirmed in all but one patient in this cohort) 
was congenital in onset, as it was apparent as a delay in early language acquisition or evident 
on the first formal audiometric testing performed. Primary ovarian insufficiency was present in all 
post-pubertal females in this cohort, as confirmed by abnormally high follicle stimulating 
hormones (FSH) levels when evaluated for amenorrhea (P1) or infertility (P4 and P6). The 
manifestations of sensorineural hearing loss and primary ovarian insufficiency were not related 
to the severity of the muscular dystrophy. While we were not able to obtain andrological 
examinations on the post-pubertal male patients in our series, none of the five male adult 
patients has had children. Of interest, reduced expression of GGPPS in testis has been linked 
to infertility in men.19, 20  
 
The sensorineural hearing loss observed in patients with GGPS1-related muscular dystrophy is 
most likely sensory organ related and localized to the organ of Corti, consistent with cochlear 
implantation being highly effective in all four patients in our cohort who underwent implantation. 
Hereditary sensorineural hearing loss is genetically and mechanistically very heterogeneous.21, 
22 None of the recognized forms of hereditary sensorineural hearing loss has muscular 
dystrophy associated as part of the phenotype. Hearing loss may occur in combination with a 
muscular dystrophy or a myopathy in early onset facioscapulohumeral dystrophy (FSHD) 2, 23  
and Vici syndrome, a complex congenital multisystemic disorder caused by recessive mutations 
in autophagy regulator EPG5 gene, which can also be associated with sensorineural hearing 
loss,24 25 26 27 as well with a vacuolar myopathy,28 thus implicating abnormal autophagy 
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regulation in the causation of sensorineural hearing loss and myopathy. Early onset 
sensorineural hearing loss and primary ovarian insufficiency without muscular dystrophy have 
been recognized in Perrault syndrome, a syndrome that is genetically heterogeneous and 
associated thus far with mutations in the genes HSD17B4, HARS2, LARS2, CLPP and 
C10orf2,3 implicating mitochondrial and peroxisomal pathogenesis in this constellation. Patients 
with mutations in the mitochondrial tRNA synthase genes LARS2 or KARS in addition to 
sensorineural hearing loss and ovarian insufficiency may also have cerebral leukodystrophy.29  
 
Possible downstream effects of GGPPS dysfunction and thus GGPP deficiency would be 
predicted to include impaired geranylgeranylation of small GTPases of the Rab, and Rho/Rac 
families with consequences on organelles involved in autophagy (such as Rabs23/24/7b) , 
mitochondrial fission and fusion (Rab32), as well as actin filament dynamics (RhoA/Rac/Cdc42).  
A defect in the geranylgeranyl prenylation would thus be an intuitive way to tie together some of 
the multisystemic effects seen in the patients, including in muscle. In support of impaired muscle 
cell membrane healing as contributing to the dystrophic process with its high CK, we were able 
to demonstrate significant delays in membrane healing in patient fibroblast MyoD-transformed 
myoblasts and myotubes. The defective membrane healing could point to deficits of membrane 
shuttling from late endosomal compartment to the membrane (such as Rabs11b/11/4) and/or of 
mitochondria to the site of injury.30, 31 Some of the findings clinically (worsening of the weakness 
associated with diarrhea), histologically (occasional ragged red and COX deficiency fibers) and 
ultrastructurally (enlarged mitochondria) could also point to mitochondrial dysfunction as one of 
the involved mechanisms, at least for the muscle aspect of the disease in the more severe 
patients. In ongoing work, however, we have not yet been able to pinpoint a consistent change 
in the small GTPases or in the overall prenylome of the cells (not shown). Given the localization 
of the mutation, however, we would speculate that the effects are more subtle and related to the 
required precise subcellular spatial and temporal resolution of GGPPS depending on the cellular 
state and needs.  
 
Organism-wide complete inactivation of GGPPS function is not compatible with multicellular 
survival. A hypomorphic allele in drosophila causes the quemao brittle hair phenotype.32 A 
complete knock-out of Ggps-1 in the mouse is not viable, so that a floxed allele of Ggps1 in the 
mouse has been generated33 allowing for several tissue specific models to be 
created.34,19,35,36,37,38 While not completely inactivating the enzyme, the resulting GGPPS 
deficiency state caused a plethora of abnormalities by disrupting the protein FPP/GGPP 
balance resulting in both increased protein farnesylation (Rhe-b in cardiac myocyte, H-Ras in 
Sertoli cell and Rhe-b in germ cell of testis) and decreased protein geranylgeranylation (K-Ras 
in lung epithelial cell, RhoA and Rab27 in oocyte, and RhoA in skeletal muscle cell). 
Interestingly, the MCK-Cre driving muscle specific GGPPS inactivation did not cause 
abnormality in muscle fiber morphology, fiber type composition, running ability or rotarod test 
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but improved systemic insulin sensitivity by activating Irs-1/Pi3k/Akt pathway through 
decreasing RhoA geranylgeranylation. Since GGPPS enzyme activities of the mutant GGPPS 
identified in our patients were only mildly reduced, we speculate the function of these mutants 
may be different from general GGPPS activity reduction.  
 
Interference with the mevalonate pathway has been linked to human disease (Fig 3B). 
Pharmacological targeting of the mevalonate pathway includes the use of statins to block 
HMGCoA reductase, which can lead to the development of myopathy in a subset of patients.39 
Abnormal geranylgeranylation specifically has been reported in muscle biopsies from patients 
with statin myopathy as well as in cellular models40 with reduced prenylation of small GTPases 
including Rab and RhoA, and increased apoptosis.41 The anti-bone resorptive drug class of 
bisphosphonates directly inhibit farnesyl diphosphate synthase (FPPS) or geranylgeranyl 
diphosphate synthase (GGPPS). Loss of bone-resorptive activity and osteoclast apoptosis is 
due primarily to loss of geranylgeranylated small GTPases.42 In this context it is of interest that a 
rare genetic variant in GGPS1 (Asp188Tyr) has been linked to an increased fracture risk.10, 11, 43 
When expressed in cells, the Asp188Tyr variant leads to reduced enzyme activity.12 In our 
patients there was no apparent bone phenotype; however, none of the patients has been 
treated with bisphosphonates, so that it remains unclear whether our patient cohort would react 
to the drug with higher sensitivity.  
 
The specific biallelic mutations identified in this patient cohort were all extremely rare, 
recessively acting missense mutations, three of which (R261H, R261G, and F257C) were 
recurrent in different ethnic populations. All mutations except for one allele (P15S in patient 3) 
define a stretch of five amino acids in the 11th alpha helix as a functionally important 
microdomain that is specific to animal GGPPS and not seen in the plant enzyme. The changes 
induced by the mutations are not structurally dramatic, but they likely change the hydrogen 
bonding network within the helix. The domain is clearly outside the catalytic site which is located 
within the barrel formed by the ten helices, but it is facing outward where it could potentially 
interact with as yet to be defined binding partners involved in the localization or shuttling 
enzyme (Fig 4A). Only the P15S mutation is outside of the narrow five amino acid domain, but it 
occurs in compound heterozygosity with the with R261G mutation in the original domain.44 It is 
possible that P15S represents a hypomorphic allele acting in conjunction with the R261G 
missense in the commonly mutated micro-domain.  
Enzymatic activity of GGPPS in patient derived fibroblasts was only moderately impaired to 
about 50%, a degree of enzymatic dysfunction that in metabolic disease in general should not 
lead to a phenotype. In fact, heterozygous loss-of-function alleles in GGPS1 are listed in  
gnomAD in presumably normal individuals. It is thus likely that the effects of the mutations on 
GGPPS function are more subtle, for instance by impairing the dynamic subcellular localization 
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of the enzyme for cell type specific processes. It is notable that our effort to generate a knock-in 
mouse of one of the missense mutations was unexpectedly severe in that it caused embryonic 
lethality, the cause of which is not entirely clear, but strong evidence for a clear 
underdevelopment of the placental/embryonic vascular unit was evident. Small GTPases, 
including Rap1, Rho GTPases, and Rab GTPases, have previously been reported to regulate 
cell–cell junctions in various cell types and developmental stages45, 46 including for vascular and 
heart morphogenesis.45, 47, 48 While not providing a suitable model for the human disease, the 
severity of the phenotype seen in the resulting Y259C knock-in mouse confirms the sensitivity of 
organisms to GGPPS dysfunction as well as the general pathogenicity of the missense 
mutation. To address this, we are generating a new mouse line which is heterozygous for the 
knock-in allele and a floxed allele for tissue specific “unmasking” of the missense, as well as a 
knock-in line for a milder missense seen in homozygosity in some of the patients.  
  
Biallelic, highly specific missense mutations in GGPS1 in 11 patients from six independent 
families define a unique new syndrome of muscular dystrophy with associated congenital 
sensorineural hearing loss and primary ovarian insufficiency in females, while also highlighting 
the mevalonate/isoprenoid pathway as a novel, albeit still incompletely explored, pathway for 
muscular dystrophy, hearing loss, and infertility. Because of the fundamental role GGPPS plays 
in cellular processes at all levels, it is likely that the effects of the mutations described here will 
be highly specific as to their cellular mechanisms in muscle, inner ear and ovary. Shedding light 
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Figure 1: Autosomal recessive inheritance of GGPS1 mutations and phenotypic characteristics of GGPS1-
related muscular dystrophy (A) Patient pedigrees demonstrating biallelic GGPS1 mutations in six separate 
families. (B) Prominent lordosis (following spinal fixation surgery) and hip flexion, knee flexion and elbow 
flexion contractures seen in patients P1 and P2 who both demonstrate diaphragm compressing maneuvers 
including rocking back and forth or increasing intra-abdominal pressure on expiration by hand (a-d). P1 has 
a tracheostomy for ventilation (a and b), while P2 uses non-invasive ventilation in the form of bi-level 
positive airway pressure. Severe neck extension contracture evident in P2 (c) necessitating support of neck 
with hand to promote upright head posture (d). (C) Muscle MRI Findings in GGPS1-related muscular 
dystrophy. Muscle MRI performed in Family 3 [patients P6 (a and d), P4 (b and e) and P5 (c and f)] showing 
variably increased T1 signal in muscles, indicative of fatty infiltration. There is evidence of relative sparing of 
the rectus femoris, sartorius and gracilis muscles (a, b and c) and relative involvement of the soleus muscle 
(d, e and f).  There is evidence of considerably asymmetric involvement with abnormal T1 signal in the 
lateral aspect of the vastus lateralis in patient P4 on the right only (arrow) (b) and abnormal T1 signal of the 
adductor longus on the left only (arrowhead). Patient 5 (c) has asymmetric involvement of the hamstrings 
with notable involvement of the hamstrings in the right leg and relative sparing of the hamstrings in the left 
leg. 
 












Figure 2: Histological, Ultrastructural and Immunostaining Characteristics of muscle in GGPS1-related 
muscular dystrophy.  Muscle from a deltoid biopsy performed in patient P1 at 21 years (A-C) demonstrates 
nuclear internalization and a rimmed vacuole (arrow) on Gömöri Trichrome staining (A). NADH (B) and COX 
(C) stains reveal focally irregular staining including core-like regions (C). Muscle from a deltoid biopsy 
performed in patient P4 at 39 years (D-F) demonstrates a ragged red fiber (asterisk) and myophagocytosis 
(arrow) on Gömöri Trichrome staining (D). NADH (E) and COX (F) staining demonstrate mildly irregular 
staining and a COX negative fiber (asterisk) (F). EM performed on P1’s muscle biopsy (G) reveals autophagic 
material including myeloid bodies. EM of P2’s deltoid biopsy at 19 years (H and I) shows findings suggestive 
of mitophagy (H) and accumulation of subsarcolemmal mitochondria (I). P8’s quadriceps biopsy at 14 years 
(J-L) reveals ultrastructural evidence of elongated mitochondria (J) and an accumulation of autophagic 
debris (K). Further evidence of disordered autophagy is seen by positive staining for the autophagy marker 
LC3B (L). 












Figure 3: GGPPS mutations localization, conformation and the mevalonate pathway (A) Alignment of human 
GGPPS with GGPPS from other species (adapted from Kavanagh et al JBC 2006 with modifications). Red 
shaded boxes indicate the position of the mutations. Blue boxes show residues involved in protein/protein 
interactions; orange boxes show conserved catalytic residues. Red cylinders show alpha helices of hGGPPS. 
While the catalytic domain is conserved across animals and plants, the mutated residues are conserved in all 
animals including drosophila, but not in plant species, suggesting a specific role for this domain in animal 
cells. (B) The molecular weight of GGPPS produced in bacterial expression system in solution was measured 
using gel filtration. The GGPPS mutants eluted essentially at a similar point to the wild type enzyme, with 
estimated molecular size about 240-255 KD, suggesting they are presented as a hexamer. There was no 
indication of any smaller enzyme unit such as the dimer, but a small amount of aggregated protein apparent 
for mutants Y259C, R261H and R261G (arrow). Blue= WT, Red=P15S, Brown= F257C, Green= Y259C, 
Pink= R261H, Cyan= R261G. (C) The mevalonate pathway. Mevalonate is the precursor of FPP and GGPP, 
which are the substrates for prenylation enzymes. Various inhibitors in the pathway are indicated [DGBP: 
digeranyl bisphosphonate; FTI: Farnesyl protein transferase inhibitor; GGTI: GGPTase inhibitor]. 












Figure 4: GGPPS modeling (A) GGPPS hexamer overview showing the position of the mutations.  Each dimer 
is composed of a blue and a yellow monomer, the whole molecule is made up of three dimers. F257, Y259 
and R261 are shown on mon mer A (blue); P15 is shown on monomer D (yellow). The C-terminus and 
active site of monomer A are arrowed. The N-terminus of monomer D is also annotated. Mutated residues at 
C-terminus (F257, Y259 and R261) are located at an externally facing orientation of the 11th alpha helix and 
outside of the barrel of the hexamer where the catalytic activity of GGPPS is located. The P15S mutation on 
the other hand maps to the first helical domain which is in close interaction with residues 226-254 (region C 
in Fig 2A) of monomer A on the adjacent dimer, consistent with its purported role in assembly of the 
hexameric structure. (B-F) GGPPS mutant sites molecular model: Structural data was analyzed and figures 
were drawn using Molsoft Browser Pro, and PyMOL 2. (B) P15 is inducing a kink in the helix. The side chain 
of the amino acid is in a relatively large pocket, which contains a water molecule (not shown). This area 
forms the interaction zone between monomers A (dark blue) and D (yellow) of dimers A/B and C/D. The 
mutant protein has a serine in this location. The side chain volume of serine is smaller than that of proline, 
and so modeling a serine residue here using PyMOL 2 shows no steric clashes. (C) F257 (grey balls) sits just 
buried below the surface of GGPPS.  It is surrounded by mainly hydrophobic residues – Y180, H194, V248 
and L251 (transparent blue balls).  R261 (not shown) fills the gap above it. The van de Waals volume of 
phenylalanine is 135Å, so it is possible to substitute with the 86Å volume of cysteine resulting in no steric 
hinderances. (D) Y259 sits on the surface with several interactions (F215, H219). The hydroxyl of Y259 sits 
closely with the oxygen (red) atoms of glutamic acid E141 and possibly forms an interaction. Replacing Y259 
for C259 presents no steric clashes but probably abolishes any interaction with E141. (E) R261 sits on the 
outer surface of the GGPPS dimer facing the solvent.  The side chain is shown as grey spheres for carbon 
atoms, blue for nitrogen and the main chain is in green. (F) Modeling the replacement of this residue with a 
histidine highlights steric clashes with K265 and F294, however K265 can rotate to minimize this clash. 
Replacing R261 with a glycine does not appear to cause a structural clash.
 












Figure 5: GGPPS in human dermal fibroblast and skeletal muscle (A) In human dermal fibroblasts, GGPPS 
showed a rather uniform cytoplasmic expression, along with signals concentrated in some organelles and in 
the perinuclear region. No significant difference was observed between patient derived fibroblasts (P1, with 
GGPS1 compound heterozygous mutations: p.Y259C; R261G) and normal control fibroblasts. (B) GGPPS 
showed a prominent Z disc localization (Z disc labeled with desmin antibody) in the longitudinal section of 
normal human muscle biopsy. (Scale bar = 2 µm) (C) As shown in the human muscle cross section, an 
increased GGPPS immunoreactive signal was observed in the muscle of patients (P1 and P8) compared with 
normal control, with some focal, subsarcolemmal accumulation which partially co-localizes with the 
mitochondrial marker ATP synthase beta. (Scale bar = 15 µm) 
 












Figure 6: GGPPS enzyme activity and kinetics of human myoblasts/myotubes membrane repair following 
laser injury (A-B) GGPPS catalytic enzyme activity (A) in wild type and mutant GGPPS expressed in bacterial 
expression system, using 10 µM FPP/IPP as a substrate showed the P15S mutant had similar activity as wild 
type; however, the other mutants (F259C, Y259C, R261G and R261H) consistently showed a reduced 
activity (range about 70~85% of wild type activity) (n=3, technical repeats). (B) In human MyoD-converted 
myoblasts, the GGPPS enzymatic activity in pool patients’ cells (P1, P2, P6 and P8) decreased to about 50% 
of the activity in pooled control cells (P=0.1127). (C-F) Patient myoblasts and myotubes have poor 
membrane repair ability. Patient myoblasts (C) and myotubes (E) were focally injured by laser, and the 
traces show the kinetics of the FM1-43 dye fluorescence in patient myoblasts (n=93) and control myoblasts 
(n=105), indicating a delay in membrane repair in patient myoblasts (t-test, P=1.9E-24). Bar graph shows a 
greater fraction of the injured patient myoblasts failed to repair (30%) compared with control myoblasts 
(15%) (t-test, P=0.026) (D). Similarly, differentiated myotubes (E) showed significantly greater FM1-43 dye 
entry in patient myotubes (n=23) compared with control myotubes (n=31) (t-test, P=3.1E-15). Again, a 
higher proportion of the injured patient myotubes failed to repair (60%) compared with normal control 











(30%) (t-test, P=0.038). Note that myotubes have less efficient repair at baseline compared to myoblasts, 
hence the difference to the mutant line, while still significant, is less obvious (F). 












Figure 7: Generation of homozygous knock-in of Y259C mice results in delayed embryonic growth and 
embryonic lethality (A) Schematic representation of the targeting strategy for creation of a knock-in Y259C 
mutant mouse. Hatched rectangles represent Ggps1 coding sequences, grey rectangles indicate non-coding 
exon portions. The neomycin positive selection cassette is driven by a Phosphoglycerine kinase promoter 
(pGK) as indicated, and the loxP sites are represented by blue triangles and FRT sites by double red 
triangles. The initiation (ATG) and the Stop (Stop) codon used for isoform 3 where the Y259C mutation is 
present are indicated. In vivo Flp-mediated excision of the neomycin cassette is depicted. The diagram is not 
depicted to scale. (B) Photograph of a representative uterus from a heterozygous female at ED10.5 following 
mating to a heterozygous male. Arrows indicate the embryos in C-E while in the uterus. (C-E) Photographs 
of embryos for each genotype enveloped by their yolk sac with placentas following dissection from the 
uterus (B). (F-H) Embryos and placentas isolated at ED 10.5. Delayed growth in the homozygous knock-in 
embryos is shown in H. The knock-in embryo reflects the development typically observed at ED9.5 in wild 
type mice. (I-K) Recovery of all genotypes at E12.5 from heterozygous. Delayed embryonic growth in the 
homozygous embryo at ED12.5 (K) is reflective of the development of a wild type embryo at ED10.5. (L-N) 











Placentas from the ED 12.5. embryos above. The placenta from the homozygous knock-in embryo is 
reduced in size and is developmentally delayed compared to litter controls. (O) Photograph of a uterus from 
a heterozygous female at ED13.5 showing obvious differences in conceptus size. (P) Representative 
photograph of embryos in their yolk sac with placentas following dissection from the uterus for each 
genotype. A homozygote knock-in embryo in an advanced state of reabsorption is indicated with an asterisk 
(*). A wild type and a heterozygous embryo are also observed to be undergoing reabsorption in this 
pregnancy. An embryo that we were unable to extract DNA from for genotyping is indicated by (♢). 
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